<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">World J Surg Oncol</journal-id>
      <journal-id journal-id-type="iso-abbrev">World J Surg Oncol</journal-id>
      <journal-title-group>
        <journal-title>World Journal of Surgical Oncology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1477-7819</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27080037</article-id>
      <article-id pub-id-type="pmc">4831094</article-id>
      <article-id pub-id-type="publisher-id">851</article-id>
      <article-id pub-id-type="doi">10.1186/s12957-016-0851-3</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A case of disseminated carcinomatosis of the bone marrow originating from gastric cancer 3&#xA0;years after intraperitoneal chemotherapy against peritoneal carcinomatosis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Okuno</surname>
            <given-names>Takayuki</given-names>
          </name>
          <address>
            <phone>+81-3-5800-8653</phone>
            <email>OKUNOT-SUR@h.u-tokyo.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yamaguchi</surname>
            <given-names>Hironori</given-names>
          </name>
          <address>
            <email>yamaguchih-tky@umin.net</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kitayama</surname>
            <given-names>Joji</given-names>
          </name>
          <address>
            <email>kitayama-1su@h.u-tokyo.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ishigami</surname>
            <given-names>Hironori</given-names>
          </name>
          <address>
            <email>ishigami-1su@h.u-tokyo.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nishikawa</surname>
            <given-names>Takeshi</given-names>
          </name>
          <address>
            <email>takn-tky@umin.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tanaka</surname>
            <given-names>Junichiro</given-names>
          </name>
          <address>
            <email>jtan-tky@umin.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tanaka</surname>
            <given-names>Toshiaki</given-names>
          </name>
          <address>
            <email>toshi-t@venus.dti.ne.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kiyomatsu</surname>
            <given-names>Tomomichi</given-names>
          </name>
          <address>
            <email>kiyomatan@yahoo.co.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hata</surname>
            <given-names>Keisuke</given-names>
          </name>
          <address>
            <email>qyp11547@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nozawa</surname>
            <given-names>Hiroaki</given-names>
          </name>
          <address>
            <email>NOZAWAH-SUR@h.u-tokyo.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kawai</surname>
            <given-names>Kazushige</given-names>
          </name>
          <address>
            <email>kz-kawai@mvd.biglobe.ne.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kazama</surname>
            <given-names>Shinsuke</given-names>
          </name>
          <address>
            <email>kazamas-sur@h.u-tokyo.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ishihara</surname>
            <given-names>Soichiro</given-names>
          </name>
          <address>
            <email>sochan31@hotmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sunami</surname>
            <given-names>Eiji</given-names>
          </name>
          <address>
            <email>eijisunami@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Watanabe</surname>
            <given-names>Toshiaki</given-names>
          </name>
          <address>
            <email>toshwatanabe@yahoo.co.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1"><label/>Department of Surgical Oncology, The University of Tokyo, 7-3-1 Bunkyo-ku, Tokyo, 113-8655 Japan </aff>
        <aff id="Aff2"><label/>Department of Chemotherapy, The University of Tokyo, Tokyo, Japan </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>14</day>
        <month>4</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>14</day>
        <month>4</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2016</year>
      </pub-date>
      <volume>14</volume>
      <elocation-id>107</elocation-id>
      <history>
        <date date-type="received">
          <day>10</day>
          <month>6</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>24</day>
          <month>3</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Okuno et al. 2016</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Clinical studies of intraperitoneal chemotherapy with paclitaxel in patients of gastric cancer with peritoneal carcinomatosis is well tolerated and effective, and&#xA0;rare cases of metastasis and recurrence&#xA0;have experienced during the treatment. Disseminated carcinomatosis of the bone marrow&#xA0;is highly rare in gastric cancer&#xA0;and associated with&#xA0;a poor prognosis.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>A 59-year-old woman of gastric cancer with peritoneal carcinomatosis received five courses of chemotherapy with intraperitoneal administration of paclitaxel, and laparoscopy showed disappearance of the peritoneal carcinomatosis. She subsequently underwent total gastrectomy, and the histopathological findings showed a complete response to the chemotherapy. Postoperatively, chemotherapy with intraperitoneal administration of paclitaxel was continued for 30&#xA0;months, without apparent recurrence. However, the gastric cancer recurred as disseminated carcinomatosis of the bone marrow with disseminated intravascular coagulation, and we hence changed the chemotherapy regimen to weekly irinotecan. Remission was achieved, and she did not experience any major symptoms; however, she died 6&#xA0;months after the diagnosis of disseminated carcinomatosis of the bone marrow.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>Since intraperitoneal paclitaxel administration can strongly suppress peritoneal carcinomatosis of gastric cancer, careful attention should be paid not only to peritoneal recurrence but also for rare site metastases, such as bone marrow metastases.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Gastric cancer</kwd>
        <kwd>Disseminated carcinomatosis of the bone marrow</kwd>
        <kwd>Intraperitoneal chemotherapy</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>Peritoneal carcinomatosis is the most frequent mode of metastasis and recurrence in patients with gastric cancer. Clinical studies investigating the effects of intraperitoneal chemotherapy with paclitaxel (PTX) performed by our group on such patients have shown that the treatment is well tolerated and effective [<xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR3">3</xref>]. Moreover, we have experienced rare cases of metastasis and recurrence recently, such as leptomeningeal carcinomatosis [<xref ref-type="bibr" rid="CR4">4</xref>] after long-term control of peritoneal metastasis. Particularly, bone marrow metastasis is highly rare in gastric cancer [<xref ref-type="bibr" rid="CR5">5</xref>], and disseminated carcinomatosis of the bone marrow (DCBM) is known to be closely associated with disseminated intravascular coagulation (DIC) and a poor prognosis [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Herein, we present a rare case of DCBM originating from gastric cancer and developing 3&#xA0;years after intraperitoneal chemotherapy with PTX against peritoneal carcinomatosis.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>A 59-year-old woman was referred to our department for intraperitoneal chemotherapy for gastric cancer with peritoneal carcinomatosis. She had already received two courses of chemotherapy with S-1 plus cisplatin in the previous hospital. Upper intestinal endoscopy showed Borrmann type IV gastric cancer with ulceration at the upper part of the stomach (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1a, b</xref>). Pathological diagnosis was poorly differentiated tubular adenocarcinoma with the signet ring cell carcinoma. Staging laparoscopy showed a thickened omentum due to carcinomatosis (&#x201C;omental cake&#x201D;) and numerous disseminated nodules in the whole abdominal cavity. An intraperitoneal access port was implanted to allow for chemotherapy administration. After the staging laparoscopy, she received five courses of chemotherapy with intraperitoneal administration of PTX. At first, two courses with intraperitoneal administration of PTX, intravenous administration of oxaliplatin, and oral S-1 were done. Then three courses with intraperitoneal and intravenous administration of PTX and oral S-1 were done. Oxaliplatin was administered intravenously at a dose of 100&#xA0;mg/m<sup>2</sup> on day 1, and PTX was administered intravenously at a dose of 50&#xA0;mg/m<sup>2</sup> on day 1 and intraperitoneally via the access port at a dose of 20&#xA0;mg/m<sup>2</sup> on days 1 and 8, respectively. PTX was diluted in 1&#xA0;l normal saline over 1&#xA0;h. S-1 was administered orally twice daily at a dose of 80&#xA0;mg/m<sup>2</sup> per day for 14 consecutive days, followed by 7&#xA0;days without treatment. These chemotherapy in clinical studies were approved by the institutional review board of The University of Tokyo. Repeat laparoscopy showed disappearance of the peritoneal carcinomatosis (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2a</xref>&#x2013;<xref rid="Fig2" ref-type="fig">d</xref>), after which she underwent total gastrectomy with lymphadenectomy. Pathological examination revealed no viable cancer cells remaining in the resected specimen (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>). The patient received a total of 38 courses of chemotherapy with intraperitoneal and intravenous administration of PTX and oral S-1 after the gastrectomy, without apparent metastasis or recurrence.<fig id="Fig1"><label>Fig. 1</label><caption><p>Upper gastrointestinal endoscopic studies of the patient. <bold>a</bold> Borrmann type IV gastric cancer with ulceration at the upper part of the stomach was revealed. <bold>b</bold> Giant folds of the greater curvature and poor extension of the wall were shown at the middle part of the stomach</p></caption><graphic xlink:href="12957_2016_851_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig. 2</label><caption><p>Laparoscopic studies of the patient. Repeat laparoscopy is showing a disappearance of the peritoneal carcinomatosis. <bold>a</bold> Right upper quadrant of the abdomen. <bold>b</bold> Left upper quadrant of the abdomen. <bold>c</bold>, <bold>d</bold> Lower part of the abdomen</p></caption><graphic xlink:href="12957_2016_851_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig. 3</label><caption><p>Resected specimen of the patient. Pathological examination revealed no viable cancer cells remaining in the specimen</p></caption><graphic xlink:href="12957_2016_851_Fig3_HTML" id="MO3"/></fig></p>
      <p>Two years and 6&#xA0;months after the surgery, she experienced lumbago, with increases in the carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, and CA125 levels observed. Computed tomography showed bone metastases at the thoracic to lumbar vertebrae. A decreased platelet count was noted, indicating DIC, and the patient was hence readmitted to our hospital.</p>
      <p>At the time of admission, percutaneous bleeding was observed in her forearm. Blood test showed hemoglobin, 9.9&#xA0;g/dl; platelet count, 72,000/mm<sup>3</sup>; alkaline phosphatase, 1969&#xA0;IU/l; prothrombin time international normalized ratio, 1.17; fibrinogen, 346&#xA0;mg/dl; and fibrinogen degradation products, 201.1&#xA0;&#x3BC;g/ml. The patient was diagnosed as DIC, and treatment with gabexate mesilate was initiated. The tumor marker levels, including CEA (426.3&#xA0;ng/ml) and CA19-9 (2413&#xA0;IU/ml), were also further increased. Bone scintigraphy and fluorodeoxyglucose-positron emission tomography showed multiple bone metastatic lesions in the thoracic to lumbar vertebrae, costae, sternum, iliac bone, scapulae, and femora (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4a</xref>&#x2013;<xref rid="Fig4" ref-type="fig">c</xref>). DCBM from gastric cancer was clinically diagnosed, and chemotherapy was immediately commenced with a regimen of weekly irinotecan (CPT-11). On day 1, intravenous CPT-11 (100&#xA0;mg/m<sup>2</sup>, 80&#xA0;% dose) was administered, and the regimen was repeated on a weekly basis. After three courses of chemotherapy, she recovered from DIC with relief of the lumbago. The same regimen was repeated in an outpatient setting for 5&#xA0;months. However, although the patient did not show any signs of peritoneal recurrence, the tumor markers increased and DIC developed again, and the patient died of DCBM 3&#xA0;years and 5&#xA0;months after the introduction of intraperitoneal chemotherapy.<fig id="Fig4"><label>Fig. 4</label><caption><p>
<bold>a</bold>, <bold>b</bold> Bone scintigraphy and <bold>c</bold> fluorodeoxyglucose-positron emission tomography of the patients. Multiple bone metastases to the thoracic to lumbar vertebrae, costae, sternum, iliac bone, scapulae, and femora are shown, suggestive of disseminated carcinomatosis of the bone marrow</p></caption><graphic xlink:href="12957_2016_851_Fig4_HTML" id="MO4"/></fig></p>
    </sec>
    <sec id="Sec3">
      <title>Discussion</title>
      <p>In the present case, gastric cancer metastasized to the bone marrow and caused DCBM associated with DIC 3&#xA0;years after intraperitoneal chemotherapy against peritoneal carcinomatosis of gastric cancer. DCBM is uncommon in patients with gastric cancer; Kim et al. reported that only 2.4&#xA0;% of metastatic, unresectable, or recurrent gastric cancers had confirmed bone marrow metastasis [<xref ref-type="bibr" rid="CR5">5</xref>]. And DCBM from solid tumors was closely associated with DIC [<xref ref-type="bibr" rid="CR6">6</xref>]. Jarcho et al. reported an association between multiple bone metastases and DIC in diffusely infiltrative gastric cancer as early as 1936 [<xref ref-type="bibr" rid="CR7">7</xref>], and Brain et al. reported a close association between mucin-forming cancer and DIC and/or microangiopathic hemolytic anemia [<xref ref-type="bibr" rid="CR8">8</xref>]. Later, Pasquini et al. examined bone metastases from solid tumors with hematological disorders, and the prognosis is very poor [<xref ref-type="bibr" rid="CR9">9</xref>]. This condition is called DCBM [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>].</p>
      <p>In patients with DCBM and DIC from solid tumors, gastric cancer accounts for the majority of cases [<xref ref-type="bibr" rid="CR9">9</xref>]. DCBM is associated with various symptoms, including bone pain, bleeding tendencies, anemia, general weakness, and elevated levels of serum alkaline phosphatase [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Macroscopic Borrmann types III and IV, histologically poorly differentiated adenocarcinoma, younger age, highly advanced tumors, and primary tumors in the upper part of the stomach are risk factors for gastric cancer resulting in DCBM [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Of note, many cases (66.7&#xA0;%) recur over 5&#xA0;years following the initial surgery, with recurrence at the bone marrow more than 10&#xA0;years as reported in some case [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>], indicating the presence of &#x201C;tumor dormancy,&#x201D; a long latent phase of tumor progression [<xref ref-type="bibr" rid="CR13">13</xref>]. The present case matched most of these risk factors and presented all major symptoms described in the literature in the 2&#xA0;months after presenting with lumbago.</p>
      <p>DCBM is associated with a poor prognosis, with some patients dying within a few weeks as a result of bleeding or organ insufficiency caused by DIC [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Park et al. examined 203 cases of bone marrow metastasis originating from gastric cancer. They found that the median survival time was 103&#xA0;days, with complicated DIC being associated with a significantly poorer prognosis, while patients receiving chemotherapy had a better prognosis (175&#xA0;days). On the other hand, the median survival time of the patients who did not receive chemotherapy was only 43&#xA0;days [<xref ref-type="bibr" rid="CR14">14</xref>], indicating that aggressive chemotherapy is effective for DCBM [<xref ref-type="bibr" rid="CR10">10</xref>&#x2013;<xref ref-type="bibr" rid="CR12">12</xref>]. In this case, we changed the regimen to weekly CPT-11 because the patient had already received other key drugs for gastric cancer, including S-1, cisplatin, and PTX. The patient overcame DIC once and survived for 6&#xA0;months after the diagnosis of DCBM.</p>
      <p>In our previous clinical studies, we treated peritoneal carcinomatosis of gastric cancer using intraperitoneal chemotherapy with PTX. In this intraperitoneal chemotherapy, PTX is repeatedly administered into the intraperitoneal space via a subcutaneously placed intraperitoneal access port. This combination chemotherapy is effective for peritoneal metastases and appears to produce a marked elongation of survival in these patients [<xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR3">3</xref>]. Moreover, peritoneal carcinomatosis often disappears macroscopically during the course of intraperitoneal chemotherapy. From August 2005 to April 2012, 158 cases of gastric cancer with peritoneal carcinomatosis underwent intraperitoneal chemotherapy with PTX in our department. Recurrence in the bone was found in 15 cases (9.5&#xA0;%), with multiple bones implicated in 4 cases (2.5&#xA0;%); of these, 3 cases (1.8&#xA0;%) were clinically suspected as DCBM with DIC. Two of these three cases (with the exception of the present case) were treated with best supportive care and died within 1&#xA0;month. The higher rate of DCBM experienced in our department compared with that in previous reports may be due to the strong suppression of peritoneal carcinomatosis by intraperitoneal administration of PTX.</p>
    </sec>
    <sec id="Sec4">
      <title>Conclusions</title>
      <p>We here experienced a patient of gastric cancer with peritoneal carcinomatosis who developed DCBM 3&#xA0;years after initiation of intraperitoneal chemotherapy with PTX. Since intraperitoneal PTX administration can strongly suppress peritoneal carcinomatosis of gastric cancer, careful attention should be paid not only to peritoneal recurrence but also for rare site metastases, such as bone marrow metastases, during the course of intraperitoneal chemotherapy.</p>
      <sec id="Sec5">
        <title>Consent</title>
        <p>Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
      </sec>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>CA</term>
          <def>
            <p>carbohydrate antigen</p>
          </def>
        </def-item>
        <def-item>
          <term>CEA</term>
          <def>
            <p>carcinoembryonic antigen</p>
          </def>
        </def-item>
        <def-item>
          <term>CPT-11</term>
          <def>
            <p>irinotecan</p>
          </def>
        </def-item>
        <def-item>
          <term>DCBM</term>
          <def>
            <p>disseminated carcinomatosis of the bone marrow</p>
          </def>
        </def-item>
        <def-item>
          <term>DIC</term>
          <def>
            <p>disseminated intravascular coagulation</p>
          </def>
        </def-item>
        <def-item>
          <term>PTX</term>
          <def>
            <p>paclitaxel</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>TO contributed to the acquisition and analysis of data and drafting of the work. HY contributed to the drafting of the work and surgery. JK and HI contributed to the revision of the work and surgery. TK, JT, TT, KH, HN, KK, SK, SI, and ES revised the work. TW gave final approval and took overall responsibility for the published work. All authors read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>This study was conducted without funding.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ishigami</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kitayama</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Otani</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kamei</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Soma</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Miyato</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer</article-title>
          <source>Oncology</source>
          <year>2009</year>
          <volume>76</volume>
          <fpage>311</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="doi">10.1159/000209277</pub-id>
          <pub-id pub-id-type="pmid">19299904</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ishigami</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kitayama</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kaisaki</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hidemura</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Otani</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis</article-title>
          <source>Ann Oncol</source>
          <year>2010</year>
          <volume>21</volume>
          <fpage>67</fpage>
          <lpage>70</lpage>
          <pub-id pub-id-type="doi">10.1093/annonc/mdp260</pub-id>
          <pub-id pub-id-type="pmid">19605503</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamaguchi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kitayama</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ishigami</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Emoto</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yamashita</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Watanabe</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis</article-title>
          <source>Cancer</source>
          <year>2013</year>
          <volume>119</volume>
          <fpage>3354</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1002/cncr.28204</pub-id>
          <pub-id pub-id-type="pmid">23798046</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Emoto</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ishigami</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yamaguchi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yamashita</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kaisaki</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kitayama</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Frequent development of leptomeningeal carcinomatosis in patients with peritoneal dissemination of gastric cancer</article-title>
          <source>Gastric Cancer</source>
          <year>2011</year>
          <volume>14</volume>
          <fpage>390</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="doi">10.1007/s10120-011-0064-y</pub-id>
          <pub-id pub-id-type="pmid">21667135</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Yi</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Jun</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>JO</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>YS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical outcome of gastric cancer patients with bone marrow metastases</article-title>
          <source>Oncology</source>
          <year>2007</year>
          <volume>73</volume>
          <fpage>192</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1159/000127386</pub-id>
          <pub-id pub-id-type="pmid">18418012</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kusumoto</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Haraguchi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nozuka</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Oda</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tsuneyoshi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Iguchi</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Characteristic features of disseminated carcinomatosis of the bone marrow due to gastric cancer: the pathogenesis of bone destruction</article-title>
          <source>Oncol Rep</source>
          <year>2006</year>
          <volume>16</volume>
          <fpage>735</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="pmid">16969487</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jarcho</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Diffusely infiltrative carcinoma: a hitherto undescribed correlation of several varieties of tumor metastasis</article-title>
          <source>Arch Pathol</source>
          <year>1936</year>
          <volume>22</volume>
          <fpage>674</fpage>
          <lpage>96</lpage>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brain</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Azzopardi</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Pineo</surname>
              <given-names>GF</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Dacie</surname>
              <given-names>JV</given-names>
            </name>
          </person-group>
          <article-title>Microangiopathic haemolytic anaemia and mucin-forming adenocarcinoma</article-title>
          <source>Br J Haematol</source>
          <year>1970</year>
          <volume>18</volume>
          <fpage>183</fpage>
          <lpage>93</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2141.1970.tb01433.x</pub-id>
          <pub-id pub-id-type="pmid">5439525</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pasquini</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Gianni</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Aitini</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Nicolini</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fattori</surname>
              <given-names>PP</given-names>
            </name>
            <name>
              <surname>Cavazzini</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Acute disseminated intravascular coagulation syndrome in cancer patients</article-title>
          <source>Oncology</source>
          <year>1995</year>
          <volume>52</volume>
          <fpage>505</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1159/000227520</pub-id>
          <pub-id pub-id-type="pmid">7478440</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kwon</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Yun</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>KH</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>SC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical outcome of gastric cancer patients with bone marrow metastases</article-title>
          <source>Cancer Res Treat</source>
          <year>2011</year>
          <volume>43</volume>
          <fpage>244</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.4143/crt.2011.43.4.244</pub-id>
          <pub-id pub-id-type="pmid">22247710</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Noda</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Sano</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Shirao</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ono</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Katai</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sasako</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A case of bone marrow recurrence from gastric carcinoma after a nine-year disease-free interval</article-title>
          <source>Jpn J Clin Oncol</source>
          <year>1996</year>
          <volume>26</volume>
          <fpage>472</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="doi">10.1093/oxfordjournals.jjco.a023267</pub-id>
          <pub-id pub-id-type="pmid">9001355</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kammori</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Seto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Haniuda</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kawahara</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Takubo</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Endo</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A case of bone metastasis from gastric carcinoma after a nine-year disease-free interval</article-title>
          <source>Jpn J Clin Oncol</source>
          <year>2001</year>
          <volume>31</volume>
          <fpage>407</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1093/jjco/hye074</pub-id>
          <pub-id pub-id-type="pmid">11574636</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Holmgren</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>O&#x2019;Reilly</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Folkman</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression</article-title>
          <source>Nat Med</source>
          <year>1995</year>
          <volume>1</volume>
          <fpage>149</fpage>
          <lpage>53</lpage>
          <pub-id pub-id-type="doi">10.1038/nm0295-149</pub-id>
          <pub-id pub-id-type="pmid">7585012</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Park</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Rha</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Hyung</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>HC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A prognostic model to predict clinical outcome in gastric cancer patients with bone metastasis</article-title>
          <source>Oncology</source>
          <year>2011</year>
          <volume>80</volume>
          <fpage>142</fpage>
          <lpage>150</lpage>
          <pub-id pub-id-type="doi">10.1159/000328507</pub-id>
          <pub-id pub-id-type="pmid">21677462</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
